Prosecution Insights
Prosecution Insights
10 pending office actions • 4 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (30%) |
| §103 only | 1 (10%) |
| §112 only | 3 (30%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 2 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPOLIS, ALEXANDRA ROSE | 2 | 39.3% | +70.3% |
| ZARA, JANE J | 1 | 70.9% | +16.1% |
| CHONG, KIMBERLY | 1 | 72.4% | +12.8% |
| TATGE, LEXUS MARC | 1 | 50.0% | +100.0% |
| SU-TOBON, QIWEN NMN | 1 | 75.0% | +100.0% |
| KONOPKA, CATHERINE ANNE | 1 | 58.2% | +64.5% |
| LEITH, NANCY J | 1 | 74.7% | +43.8% |
| MONTANARI, DAVID A | 1 | 64.8% | +49.2% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 60.3% | +35.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251183 | COMPOSITIONS COMPRISING AN RNA GUIDE TARGETING BCL11A AND USES THEREOF | KONOPKA, CATHERINE ANNE | 50d |
| 18682774 | COMPOSITIONS COMPRISING A VARIANT CAS12I3 POLYPEPTIDE AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| 18273349 | COMPOSITIONS COMPRISING A NUCLEASE AND USES THEREOF | TATGE, LEXUS MARC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17497725 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | DACE DENITO, ALEXANDRA GERALDINE | 45d overdue |
| 18251183 | COMPOSITIONS COMPRISING AN RNA GUIDE TARGETING BCL11A AND USES THEREOF | KONOPKA, CATHERINE ANNE | 50d |
| 18682774 | COMPOSITIONS COMPRISING A VARIANT CAS12I3 POLYPEPTIDE AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| 18565575 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING HYDROXYACID OXIDASE 1 (HAO1) AND USES THEREOF | ZARA, JANE J | — |
| 18281201 | COMPOSITIONS COMPRISING A VARIANT POLYPEPTIDE AND USES THEREOF | CHONG, KIMBERLY | — |
| 18274697 | CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME | LIPPOLIS, ALEXANDRA ROSE | — |
| 18273349 | COMPOSITIONS COMPRISING A NUCLEASE AND USES THEREOF | TATGE, LEXUS MARC | — |
| 18262086 | CAS12I2 FUSION MOLECULES AND USES THEREOF | SU-TOBON, QIWEN NMN | — |
| Art Unit | Apps |
|---|---|
| 1636 | 4 |
| 1637 | 2 |
| 1635 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682774 | COMPOSITIONS COMPRISING A VARIANT CAS12I3 POLYPEPTIDE AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — | §101§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18565575 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING HYDROXYACID OXIDASE 1 (HAO1) AND USES THEREOF | ZARA, JANE J | — | §112 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18281201 | COMPOSITIONS COMPRISING A VARIANT POLYPEPTIDE AND USES THEREOF | CHONG, KIMBERLY | 1636 | §112DP | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18274697 | CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18273349 | COMPOSITIONS COMPRISING A NUCLEASE AND USES THEREOF | TATGE, LEXUS MARC | 1637 | §101§103§112 | Non-Final OA | — | Pending | Jul 20, 2023 |
| 18262086 | CAS12I2 FUSION MOLECULES AND USES THEREOF | SU-TOBON, QIWEN NMN | 1636 | §103§112DP | Non-Final OA | — | Pending | Jul 19, 2023 |
| 18251183 | COMPOSITIONS COMPRISING AN RNA GUIDE TARGETING BCL11A AND USES THEREOF | KONOPKA, CATHERINE ANNE | 1635 | §101§102§103§112Other | Non-Final OA | 50d | Pending | Apr 28, 2023 |
| 16626932 | NOVEL CRISPR RNA TARGETING ENZYMES AND SYSTEMS AND USES THEREOF | LEITH, NANCY J | 1636 | §112Other | Final Rejection | — | Pending | Mar 17, 2023 |
| 17832114 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING LACTATE DEHYDROGENASE A (LDHA) AND USES THEREOF | MONTANARI, DAVID A | 1632 | §112Other | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17497725 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | DACE DENITO, ALEXANDRA GERALDINE | 1636 | DP | Non-Final OA | 45d overdue | Pending | Oct 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial